Pinealon
- Category
- Bioregulators
- Administration routes
- InjectableOral
- Regulatory status
- Not FDA-approved
A synthetic tripeptide (Glu-Asp-Arg) bioregulator that targets the pineal gland, marketed for neuroprotection, memory, and anti-aging. The evidence is weak: benefits rest almost entirely on cell and animal work from a single research lineage, and the few human claims (cognition after brain injury) are low-confidence. There is essentially no human safety data, and most supply is research-grade material of uncertain purity. Not an approved drug in the US.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Pinealon is a synthetic three-amino-acid peptide bioregulator originally isolated from a brain-protecting drug called Cortexin (derived from animal brain tissue). Developed at the St. Petersburg Institute of Bioregulation and Gerontology, it was identified as one of the shortest and most active neuroprotective sequences within that larger compound and then synthesized as a standalone molecule. Pinealon is named for its connection to the pineal gland and its influence on the serotonin-melatonin pathway that governs sleep and circadian rhythms. It is sold as a dietary supplement, not as a pharmaceutical.
How it works in the body
A tripeptide (Glu-Asp-Arg) studied in neuronal models. Cortical-culture experiments measured serotonin expression, and docking suggested interaction with the tryptophan-hydroxylase gene. These experiments did not establish pineal-cell targeting, increased melatonin production or circadian normalization.
Research overview
Pinealon is small enough to cross cell membranes and enter the nucleus, where it binds directly to DNA and influences gene activity. Its key effect is boosting the production of tryptophan hydroxylase — the enzyme that kick-starts the biochemical chain from tryptophan to serotonin to melatonin. This means it may support both mood (serotonin) and sleep (melatonin) regulation. It also activates antioxidant defenses and reduces markers of cell death in brain tissue. In animal studies, Pinealon protected neurons from oxidative damage, prevented the loss of dendritic spines (the connection points between brain cells) in an Alzheimer's disease mouse model, and improved cognitive function in rats with brain injury. Limited human data from two small studies (72 traumatic brain injury patients and 32 patients with chronic brain conditions) showed improved memory and cognitive function. The evidence base includes about 12-15 papers, but all originate from one Russian research group, no independent replication exists, and the human studies were not randomized controlled trials by Western standards.
Who researches Pinealon?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching cognitive enhancement
Studied for neuroprotective effects, memory, or cognitive performance.
People exploring sleep quality improvement
Researched for effects on sleep architecture, circadian rhythm, or sleep quality.
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(6)
Rated by level of concern
All safety data from Khavinson-affiliated research groups with small samples
HighPMC7795577; the published literature comes from a single research group
Upregulates serotonin synthesis (theoretical serotonergic interaction)
TheoreticalPMC7795577 (Molecules 2021)
Modulates neuronal excitability via NMDA/ERK pathways
TheoreticalPMC7795577; PMC3342713; Rejuvenation Res 2011 (ERK1/2)
Research-grade product not made to pharmaceutical standards
HighVendor labeling / regulatory status (not FDA-approved)
Pregnancy/breastfeeding listed as contraindications
ModerateVendor/monograph contraindication listings
Mild headaches, dizziness, GI discomfort reported
LowPMC7795577; peptide monograph safety summaries
Interaction summary(4)
Rated by direction with this peptide
Serotonergic agents (SSRIs, SNRIs, MAOIs, triptans)
CautionTheoreticalPinealon increased serotonin synthesis and tryptophan hydroxylase expression in vitro, so an additive serotonergic effect is mechanistically conceivable, though no clinical serotonergic reaction has ever been reported. Direction (Caution) and severity (Theoretical) are correct given the purely in vitro basis.
PMC7795577 (Molecules 2021)
NMDA-receptor modulators (memantine, ketamine)
SynergisticTheoreticalEDR is proposed to attenuate NMDA/glutamate excitotoxicity; co-use with NMDA antagonists could be additive on excitotoxicity protection, but the interaction is entirely unstudied in humans. Synergistic/Theoretical is the mechanistically-supported framing.
PMC3342713; PMC7795577
Pro-oxidant chemotherapy / radiotherapy (e.g., anthracyclines, platinum agents, ionizing radiation)
CautionTheoreticalBy suppressing ROS and inducing SOD2/GPX1, an antioxidant peptide could in principle blunt therapies that rely on oxidative stress for tumor kill; mechanism-based caution only, no clinical data. This is a legitimate, clinically meaningful antioxidant-class caution and correctly rated Caution/Theoretical.
Mechanistic (ROS/antioxidant findings, PMC7795577; Rejuvenation Res 2011)
Other neuro-peptide bioregulators / nootropics (Cortexin, Cerebrolysin, Semax, Selank, racetams)
SynergisticTheoreticalUsing Pinealon with other neuropeptide bioregulators or nootropics could add neuroprotective or cognitive effects through plausibly complementary mechanisms, but no controlled interaction or combination-safety data exist. Rated Theoretical because no interaction has been demonstrated; the Synergistic direction reflects a hypothesized, not established, additive effect.
Clinical-practice/usage pattern; no controlled interaction studies
Known risks(6)
Limited safety data and lack of independent validation
ModerateAll safety data originates from Khavinson-affiliated research groups with small sample sizes. No independent safety monitoring, pharmacovigilance, or large-scale safety trials have been conducted. No FDA review of safety has occurred. No dedicated English-language safety studies exist. The absence of adverse events in published studies may reflect small sample sizes rather than true absence of risk.
Potential interactions with neuropsychiatric medications
ModeratePinealon upregulates serotonin synthesis through epigenetic activation of tryptophan hydroxylase. Co-administration with SSRIs, SNRIs, MAO inhibitors, or other serotonergic medications could theoretically increase risk of serotonin syndrome. Its effects on brain neurochemistry (adrenergic mediators, serotonin, melatonin pathways) warrant caution in patients on psychiatric medications.
Caution in seizure disorders and neurological conditions
ModeratePinealon modulates neuronal excitability through NMDA-related and ERK/MAPK pathways. Individuals with epilepsy, seizure disorders, bipolar disorder, major depression, severe anxiety, or prior psychosis may face elevated risk. No studies have specifically evaluated Pinealon safety in these populations.
Unregulated product quality (research-grade sources)
ModerateUnregulated Pinealon products sold online are not manufactured under pharmaceutical GMP standards and is not subject to FDA quality oversight. Purity, identity, and sterility may vary among unregulated products sold online. Research-grade products are unsuitable for human consumption. Contamination or incorrect peptide sequences are potential concerns.
Contraindicated in pregnancy, lactation, and active cancer
Moderate (specific populations)Pregnancy and breastfeeding are listed as contraindications. Pinealon's epigenetic gene-regulatory activity and promotion of proliferative processes raise theoretical concerns in cancer patients, and active cancer or cancer history is listed as a contraindication by clinical sources. No reproductive, developmental, or oncological safety studies have been published.
Mild transient side effects
LowCommonly reported side effects include mild headaches, dizziness, gastrointestinal discomfort (nausea, bloating, gas, diarrhea), injection site reactions, fatigue, lightheadedness, flushing, and sleep disturbances. These are typically transient and self-resolving. Allergic reactions to peptide components are possible.
Drug interactions(6)
SSRIs (fluoxetine, sertraline, paroxetine, escitalopram)
Pinealon upregulates serotonin synthesis through epigenetic activation of tryptophan hydroxylase. Co-administration with SSRIs, which prevent serotonin reuptake, could theoretically lead to excessive serotonergic activity and increase the risk of serotonin syndrome. No interaction studies have been conducted. Caution is warranted.
SNRIs (venlafaxine, duloxetine) and MAO inhibitors (selegiline, phenelzine)
Similar serotonergic concern as with SSRIs. MAO inhibitors prevent the breakdown of serotonin, and combining with Pinealon's serotonin synthesis-enhancing effects could compound the risk. The combination of MAO inhibitors with any serotonin-enhancing agent is generally contraindicated.
Melatonin and melatonin receptor agonists (ramelteon, tasimelteon)
Pinealon upregulates the tryptophan-serotonin-melatonin biosynthetic cascade. Concurrent use with exogenous melatonin or melatonin agonists could lead to excessive melatonergic activity. Effects on sleep architecture and circadian function are unpredictable when combined. No interaction data exists.
Anticonvulsants / antiepileptic drugs
Pinealon modulates neuronal excitability through NMDA-related pathways and MAPK/ERK signaling. Theoretical interaction with anticonvulsant mechanisms has not been studied. Pinealon is cautioned against use in seizure disorders; its neurochemical effects could potentially alter seizure thresholds.
Other Khavinson peptide bioregulators (Epithalon, Cortexin, Vesugen)
Meshchaninov et al. 2015 tested Pinealon alongside Vesugen without reported adverse interactions. No formal interaction studies have been conducted between Khavinson bioregulators.
Antipsychotics and dopaminergic agents
Pinealon's effects on neurotransmitter synthesis (serotonin, adrenergic mediators) and neuronal signaling pathways could theoretically interact with antipsychotic medications or dopaminergic agents. No interaction data exists. Caution is warranted in patients with psychiatric conditions.
Research & benefits
Evidence base
- Evidence Level
- Limited Evidence
- Total Studies
- 12
- Human Studies
- 2
The clinical evidence for Pinealon is limited but consistent across multiple experimental models. The strongest human evidence comes from a clinical study in 72 patients with traumatic brain injury consequences showing improved memory, cognitive function, and emotional stability with oral Pinealon added to standard therapy. A second human study in 32 elderly patients with organic brain syndrome demonstrated geroprotective effects on biological aging markers. Neither study was a randomized, double-blind, placebo-controlled trial by modern Western standards. Preclinical evidence is stronger and more mechanistically detailed: Pinealon prevents dendritic spine loss in 5xFAD Alzheimer's model neurons (71% increase in mushroom spines), suppresses ROS accumulation dose-dependently, stimulates serotonin expression through epigenetic regulation of tryptophan hydroxylase, and protects against hypoxia-induced neurodegeneration. The major limitations are: Khavinson-group origin for nearly all studies, small sample sizes, lack of independent replication, and absence of formal clinical development outside Russia.
Researched for(6)
Rated by confidence in the evidence
Neuroprotection via antioxidant activity and suppression of reactive oxygen species
LowDose-dependent ROS reduction in several cell types and two rat studies, no human data yet.
PMC7795577 (Molecules 2021); Rejuvenation Res 2011, doi:10.1089/rej.2011.1172; PMC3342713
Prevention of dendritic spine loss in Alzheimer's disease models
SpeculativeCulture experiments and a live-mouse 5xFAD study reported spine effects; human benefit remains unproven.
PMC7795577 (Molecules 2021)
Increased serotonin expression in young rat cortical cultures; proposed epigenetic mechanism
SpeculativeSerotonin expression increased significantly in young cortical cultures; the old-culture increase was nonsignificant. The mechanism was modeled.
PMC7795577 (Molecules 2021)
Antihypoxic neuroprotection and stimulation of endogenous antioxidant enzymes
LowRat studies raised brain antioxidant enzymes and improved hypoxia resistance, no human data.
PMC7795577 (Molecules 2021); PMC3342713
Improved cognitive function and memory in traumatic brain injury patients
LowOne small uncontrolled trial of 72 patients reported better memory, no randomized evidence.
PMC7795577 (Molecules 2021)
Geroprotective effects and slowed biological aging in patients with organic brain syndrome
SpeculativeA small Pinealon/Vesugen study reported biological-age indicators; it does not establish slower human aging.
PMC7795577 (Molecules 2021)
Benefits(6)
Neuroprotection via antioxidant activity and suppression of reactive oxygen species
Khavinson et al. 2011 (Rejuvenation Research, PMID 21978084) — Pinealon demonstrated dose-dependent restriction of reactive oxygen species (ROS) accumulation in cerebellar granule cells, neutrophils, and PC12 cells under oxidative stress. Decreased necrotic cell death measured by propidium iodide test. At lower concentrations, antioxidant effects predominated; at higher concentrations, direct genomic interaction and cell cycle modulation continued, indicating dual mechanisms. Arutjunyan et al. 2012 (International Journal of Clinical and Experimental Medicine, PMID 22567179) — Pinealon administered to pregnant rats with hyperhomocysteinemia improved offspring spatial orientation and learning ability, decreased ROS accumulation and necrotic cells in cerebellar neurons. Protective action was directed at decreasing the toxic effect of homocysteine without reducing homocysteine levels themselves.
Prevention of dendritic spine loss in Alzheimer's disease models
Kraskovskaya et al. 2017 (PMID 28853087) reported a 71% increase in mushroom spines in mouse hippocampal cultures exposed to amyloid. Khavinson et al. 2021 studied dendritic spines in 5xFAD mice; EDR peptide prevented dendritic spine loss in 5xFAD-M mice. Molecular docking predicted potential promoter-binding sites; causal gene regulation was proposed.
Increased serotonin expression in young rat cortical cultures; proposed epigenetic mechanism
Khavinson et al. 2014 (Bulletin of Experimental Biology and Medicine, PMID 24909721) — EDR significantly increased serotonin expression in young cortical cultures; its increase in old cultures was not significant. KED increased expression in both. Molecular docking indicated that the CCTGCC nucleotide sequence in the 5-tryptophan hydroxylase gene promoter is complementary to these peptides, suggesting possible epigenetic regulation of the rate-limiting enzyme in serotonin synthesis. Authors concluded the peptides demonstrate neuro- and geroprotective activities through regulation of serotonin synthesis pathways.
Antihypoxic neuroprotection and stimulation of endogenous antioxidant enzymes
Kozina 2008 (Advances in Gerontology, PMID 18546825) — Among four bioregulatory peptides tested (vilon, epitalon, vesugen, pinealon), Pinealon showed the most pronounced antihypoxic effect in a model of hypobaric hypoxia. Mechanism involved stimulation of endogenous antioxidant enzymes (superoxide dismutase, glutathione peroxidase) rather than direct ROS scavenging, and limiting the excitotoxic effect of N-methyl-D-aspartate (NMDA). Mendzheritskii et al. 2014 (Advances in Gerontology, PMID 25051764) — In aged rats under acute hypoxia, Pinealon promoted neurogenesis and decreased neuroinflammatory reactions, normalizing cytokine levels and caspase-3 activity in brain tissue.
Improved cognitive function and memory in traumatic brain injury patients
A study referenced in Khavinson et al. 2020 (PMID 33396470) and multiple secondary sources gave oral Pinealon (0.2 mg twice daily for 20-30 days) to 72 patients with traumatic brain injury consequences and cerebrasthenia. With Pinealon added to standard therapy, patients showed improved memory, reduced duration and intensity of headaches, emotional balance, enhanced performance efficacy, regression of focal symptoms, and improvement in speech in patients with motor or sensory aphasia. Proof-correction testing showed decreased errors and increased integral workability index.
Geroprotective effects and slowed biological aging in patients with organic brain syndrome
Meshchaninov et al. 2015 (Advances in Gerontology, PMID 26390612) — In 32 patients (ages 41-83) with chronic polymorbidity and organic brain syndrome, synthetic peptides Pinealon and Vesugen demonstrated significant anabolic effects and improved central nervous system activity, slowing aging rate by biological age indicators. Both peptides were deemed safe regarding nuclear genetic effects with no impact on chromatin condensation.
Key studies(10)
Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes
Experimental research (in vitro, multiple cell types)Cerebellar granule cells, neutrophils, PC12 cellsCell culture experimentKhavinson V, Ribakova Y, Kulebiakin K, Vladychenskaya E, Kozina L, Arutjunyan A, Boldyrev A
Rejuvenation Research
2011
Pinealon demonstrated dose-dependent suppression of reactive oxygen species (ROS) accumulation in cerebellar granule cells, neutrophils, and PC12 cells under oxidative stress. Decreased necrotic cell death measured by propidium iodide test. Restriction of ROS accumulation saturated at lower concentrations while cell cycle modulation continued at higher concentrations, indicating Pinealon interacts directly with the cell genome. Pinealon modulated ERK 1/2 activity, activating proliferative processes in PC12 cells.
Pinealon protects the rat offspring from prenatal hyperhomocysteinemia
Experimental animal study (rat)Pregnant Wistar rats and offspringPrenatal treatment period through postnatal cognitive assessmentArutjunyan A, Kozina L, Stvolinskiy S, Bulygina Y, Mashkina A, Khavinson V
International Journal of Clinical and Experimental Medicine
2012
Pinealon administered to pregnant rats with diet-induced hyperhomocysteinemia significantly improved offspring spatial orientation and learning ability. Decreased both ROS accumulation and necrotic cell number in cerebellar neurons of offspring. Protective action was directed at reducing the toxic effect of homocysteine on developing brain tissue without reducing homocysteine levels, demonstrating neuroprotection independent of homocysteine metabolism.
EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease
Review article105+ references reviewedN/A (review)Khavinson V, Linkova N, Kozhevnikova E, Trofimova S
Molecules
2020
Comprehensive review identifying EDR peptide's potential to influence multiple Alzheimer's-related pathways: delayed ERK1/2 activation in homocysteine-exposed cerebellar neurons, increased SOD2 and GPx1 enzyme activity in hypoxia-sensitive brain tissue, reduced caspase-3 expression with improved learning in acute hypoxia models, enhanced PPARA and PPARG gene expression under stress conditions, and restored dendritic spine morphology in AD model neurons. The peptide normalizes behavioral responses in animal studies and improves memory in elderly patients.
Neuroprotective Effects of Tripeptides — Epigenetic Regulators in Mouse Model of Alzheimer's Disease
Experimental research (transgenic mouse model, in vitro)5xFAD transgenic Alzheimer's mice and hippocampal neuron culturesDaily administration; culture experimentsKhavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M
Pharmaceuticals (Basel)
2021
EDR and KED peptides prevented dendritic spine loss in 5xFAD transgenic Alzheimer's model mice. The 71% increase in mushroom spines in cultured hippocampal neurons comes from a separate 2017 experiment (PMID 28853087), not this study. Docking predicted candidate promoter-binding sites, suggesting an epigenetic mechanism.
Short peptides stimulate serotonin expression in cells of brain cortex
In vitro experimental study (aging rat brain cortex cells)Primary cultures of aging brain cortex cellsCell culture experimentKhavinson VKh, Lin'kova NS, Tarnovskaya SI, Umnov RS, Elashkina EV, Durnova AO
Bulletin of Experimental Biology and Medicine
2014
EDR significantly increased serotonin expression in young cultures; only KED showed a significant increase in old cultures. Molecular docking indicated that the CCTGCC nucleotide sequence in the 5-tryptophan hydroxylase gene is complementary to these peptides, suggesting possible epigenetic regulation of the rate-limiting enzyme in serotonin biosynthesis.
Investigation of antihypoxic properties of short peptides
Experimental animal study (rat, comparative)Wistar rats; four peptides compared (vilon, epitalon, vesugen, pinealon)Hypobaric hypoxia modelKozina LS
Advances in Gerontology
2008
Pinealon (Glu-Asp-Arg) demonstrated the most pronounced antihypoxic effect among all four tested bioregulatory peptides. Mechanism involved stimulation of endogenous antioxidant enzymes (superoxide dismutase, glutathione peroxidase) in brain and liver tissue, rather than direct ROS scavenging. Also limited the excitotoxic effect of NMDA during prenatal hypoxic stress.
Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon
Experimental animal study (aged rats)Old rats under acute hypoxic hypoxiaAcute hypoxia model with pre-treatmentMendzheritskii AM, Karantysh GV, Ryzhak GA, Dem'ianenko SV
Advances in Gerontology
2014
Pinealon promoted neurogenesis and decreased neuroinflammatory reactions in brain tissue of aged rats subjected to acute hypoxia, normalizing cytokine levels (IL-6, TNF-alpha) and reducing caspase-3 activity. Compared to Cortexin, Pinealon showed more pronounced effects on neurogenesis and neuroinflammation reduction.
Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission
Clinical study (non-randomized, human)32 patients (18 men, 12 women, ages 41-83)Not specified in abstractMeshchaninov VN, Tkachenko EL, Zharkov SV, Gavrilov IV, Katyreva YuE
Advances in Gerontology
2015
Synthetic peptides Pinealon and Vesugen demonstrated significant anabolic effects and improved central nervous system activity and vital organ function, slowing the rate of aging by biological age indicators. Both peptides were safe regarding nuclear genetic effects with no impact on chromatin condensation. Vesugen showed more visible geroprophylactic effects than Pinealon. Recommended as neuroprotective geroprotectors for patients with organic brain syndrome.
Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction
Biophysical research (spectroscopy, NMR, computational modeling)N/A (biophysical study)Silanteva IA, Komolkin AV, Morozova EA, Vorontsov-Velyaminov PN, Kasyanenko NA
Journal of Physical Chemistry B
2019
Demonstrated that the EDR peptide can partly penetrate into the major groove of DNA and affect base atoms, mainly N7 and O6 of guanine. Magnesium ions enhance the peptide-DNA interaction through effective screening of negatively charged phosphate groups, with this effect persisting in saline conditions. Provides biophysical evidence for the proposed epigenetic mechanism of Pinealon.
Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia
Experimental animal study (aged rats)18-month aged rats under hypoxia and hypothermiaAcute stress modelsMendzheritsky AM, Karantysh GV, Ryzhak GA, Prokofiev VN
Advances in Gerontology
2015
Both Pinealon and Cortexin promoted accumulation of adrenergic mediators in rat brains during acute hypobaric hypoxia and increased serotonin in cerebral cortex during mild hypothermia, suggesting geroprotective effects through neurotransmitter modulation. Cortexin showed more pronounced effects on free radical processes and caspase-3 activity in brain than Pinealon.
What research suggests over time
Weeks 2-4
Russian clinical useCognitive and stress-resilience improvements reported in TBI patients on Russian neurorehabilitation protocols.
Months 2-3
Russian observationalRussian observational study in 72 traumatic brain injury patients reported neurorehabilitation improvements.
Long-term
Preclinical + RussianAnimal data shows ROS suppression in cerebellar granule cells and modulation of Alzheimer's-related ERK pathways. No Western RCTs.
Regulation & availability
Why researchers look at it
Preclinical work showed a 71% increase in mushroom spines in Alzheimer's-model neurons and protection against oxidative damage, while two small human studies (72 TBI patients, 32 elderly patients) showed improved memory and cognitive function. Boosts the tryptophan-serotonin-melatonin pathway critical for mood and sleep. If independently replicated, Pinealon could become a targeted tool for the interlinked decline of sleep quality, mood, and neuroprotection in aging.
- Estimated cost
- $30-80/mo oral capsules
- FDA status
- NOT FDA-APPROVED. Pinealon has never been submitted for FDA review and holds no IND (Investigational New Drug), NDA (New Drug Application), or BLA (Biologics License Application) with the US Food and Drug Administration. It is not listed in the FDA Orange Book or the National Drug Code (NDC) directory. Pinealon is not recognized as a drug, biologic, or approved dietary supplement by the FDA. In Russia, it is classified as a peptide food supplement (not a pharmaceutical) under the Cytogen product line from the St. Petersburg Institute of Bioregulation and Gerontology. While six Khavinson peptide bioregulators (Thymalin, Cortexin, Epithalamin, Samprost, Retinalamin, and Thymogen) have been authorized by the Russian Ministry of Health as pharmaceuticals, Pinealon is not among them — it remains in the 'peptide food supplement' category. Wikipedia classifies Pinealon under 'Drugs with no legal status' and 'Drugs missing an ATC code.'
- WADA status
- NOT SPECIFICALLY PROHIBITED. Pinealon (Glu-Asp-Arg) is not individually named on the WADA 2026 Prohibited List. It does not fall under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), as it is not a growth hormone releasing factor, EPO, or growth factor. It is a short tissue-specific bioregulatory peptide with neuroprotective rather than direct performance-enhancing properties. However, WADA's prohibited list includes a catch-all provision for substances not specifically named that are 'not currently approved by any governmental regulatory health authority for human therapeutic use' — which could theoretically encompass Pinealon since it lacks FDA/EMA approval. Athletes should exercise caution and consult their national anti-doping organization or GlobalDRO.com for definitive guidance, as interpretations may vary.
- Prescribability
- Pinealon is not FDA-approved. A prescription alone does not establish eligibility to compound Pinealon. No qualifying US bulk-compounding pathway was identified in the reviewed FDA materials. In Russia and some CIS countries, it is sold in capsule form as a 'Cytogen' peptide food supplement produced under the Khavinson peptide bioregulator system, not as a pharmaceutical.
- Availability
- Pinealon is not part of mainstream Western medicine. In Russia it is sold as Pinealon capsules, a Cytogen formulation produced under the Khavinson peptide bioregulator system, and as Pinealon Lingual, a sublingual formulation. It is classified there as a peptide food supplement, not a pharmaceutical. Some functional medicine and neuropeptide-focused practitioners at international longevity clinics incorporate Pinealon into anti-aging and neuroprotective protocols, particularly for traumatic brain injury recovery, cognitive decline, and circadian dysregulation. No prescription is technically required for the supplement form in most jurisdictions, but medical supervision is advisable. Pinealon is not available through US or EU pharmacies, is not listed in any pharmacopeia outside Russia, and cannot be obtained through standard prescription channels. Availability in the US is relatively scarce compared to more established peptides.
International status
EU
Not approved
US
Not approved
Russia
Used clinically (Khavinson bioregulator protocol)
Worldwide
Limited to Russian clinical use
Regulatory timeline(15)
- 1971Vladimir Khavinson begins research on peptide bioregulators as part of a Soviet military research program at the Military Medical Academy in Leningrad (St. Petersburg).
- 1992St. Petersburg Institute of Bioregulation and Gerontology is established as Khavinson's primary research center for peptide bioregulator development.
- 2000s (early)Pinealon (Glu-Asp-Arg) is identified as one of the shortest active neuroprotective peptide sequences within Cortexin (bovine brain cortex extract) and synthesized as a standalone tripeptide at the St. Petersburg Institute.
- 2008Kozina publishes comparative study of antihypoxic properties of short peptides, identifying Pinealon as the most effective among four tested bioregulatory peptides (PMID 18546825).
- 2011Khavinson et al. publish foundational in vitro study demonstrating Pinealon suppresses ROS, decreases necrotic cell death, and modulates ERK1/2 activity in neuronal cells (PMID 21978084, Rejuvenation Research).
- 2012Arutjunyan et al. publish animal study showing Pinealon protects rat offspring from prenatal hyperhomocysteinemia-induced cognitive deficits (PMID 22567179, Int J Clin Exp Med).
- 2014Khavinson et al. report increased serotonin expression in cortical cultures and model a possible tryptophan-hydroxylase gene interaction (PMID 24909721, Bull Exp Biol Med).
- 2014Mendzheritskii et al. show Pinealon promotes neurogenesis and reduces neuroinflammation in aged rats under acute hypoxia (PMID 25051764, Advances in Gerontology).
- 2015Meshchaninov et al. publish human clinical study of Pinealon and Vesugen in 32 patients with chronic polymorbidity and organic brain syndrome, demonstrating geroprotective effects (PMID 26390612).
- 2015Mendzheritsky et al. publish comparative study of Pinealon and Cortexin in aged rats showing neurotransmitter modulation under stress conditions (PMID 28509493).
- 2019Silanteva et al. publish biophysical study in Journal of Physical Chemistry B characterizing EDR peptide-DNA interaction, demonstrating major groove binding at guanine N7 and O6 positions (PMID 30762356).
- 2020Khavinson et al. publish comprehensive review in Molecules analyzing EDR peptide mechanisms relevant to Alzheimer's disease pathogenesis, synthesizing evidence from 105+ references (PMID 33396470).
- 2021Khavinson et al. publish experimental study in Pharmaceuticals demonstrating EDR peptide prevents dendritic spine loss in 5xFAD Alzheimer's transgenic mice and increases mushroom spines by 71% in hippocampal neuron cultures (PMID 34071923).
- 2020sGains attention in Western longevity, nootropic, and biohacking communities.
- 2026-03Pinealon remains without FDA review or approval. No IND has been filed. Not included in any ongoing ClinicalTrials.gov registrations.
Sources & FAQs
Research sources(13)
- Khavinson et al. 2011 — Pinealon cell viability, ROS suppression, proliferative processes
- Arutjunyan et al. 2012 — Pinealon protects rat offspring from prenatal hyperhomocysteinemia
- Khavinson et al. 2020 — EDR peptide mechanisms in Alzheimer's disease (review)
- Khavinson et al. 2021 — Neuroprotective effects of tripeptides in 5xFAD Alzheimer's mouse model
- Khavinson et al. 2014 — Short peptides stimulate serotonin expression in brain cortex cells
- Kozina 2008 — Antihypoxic properties of short peptides
- Mendzheritskii et al. 2014 — Caspase-3 and cytokines in old rats, Pinealon vs Cortexin
- Meshchaninov et al. 2015 — Synthetic peptides in aging patients with organic brain syndrome
- Silanteva et al. 2019 — Role of ions in EDR peptide-DNA interaction
- Mendzheritsky et al. 2015 — Pinealon and Cortexin in aged rats, hypoxia and hypothermia
- Umnov et al. 2013 — Neuroprotective effects of peptide bioregulators (review)
- Pinealon — Wikipedia
- WADA 2026 Prohibited List
Frequently asked questions(6)
What is the difference between Pinealon and Cortexin?
Cortexin is a polypeptide drug derived from bovine and porcine brain cortex tissue containing a complex mixture of short peptides and is approved as a pharmaceutical in Russia. Pinealon (EDR, Glu-Asp-Arg) is one of the shortest active tripeptide sequences that was isolated from Cortexin and then synthesized as a standalone compound. Cortexin has a broader mechanism due to its multi-peptide composition, while Pinealon has a more targeted mechanism centered on serotonin synthesis regulation, antioxidant activity, and dendritic spine preservation. In comparative studies, Cortexin showed more pronounced effects on free radical processes and caspase-3 activity, while Pinealon showed stronger effects on neurogenesis and neuroinflammation reduction.
Is Pinealon safe? Are there side effects?
Human safety remains poorly characterized. A small study of Pinealon and Vesugen reported prooxidant activity and reduced circulating CD34+ cells. A study in 32 patients with organic brain syndrome found no nuclear genetic effects or chromatin condensation changes. Reported side effects from clinical practice include mild injection site reactions, headache, dizziness, gastrointestinal discomfort (nausea, bloating), fatigue, lightheadedness, flushing, and sleep disturbances, typically transient and self-resolving. No dedicated English-language safety studies exist. Safety data is limited to small studies from Khavinson-affiliated research groups. Contraindications listed include pregnancy, breastfeeding, active cancer or cancer history, epilepsy or seizure disorders, and individual component intolerance.
Can Pinealon help with Alzheimer's disease?
Pinealon has shown neuroprotective effects in Alzheimer's disease models, including a 71% increase in mushroom dendritic spines in amyloid-exposed mouse hippocampal cultures, prevention of spine loss, and docking-predicted promoter-binding sites in genes involved in AD pathogenesis (CASP3, APOE, SOD2, PPARA). These are preclinical findings from cell culture and animal models only. No human clinical trial has tested Pinealon specifically for Alzheimer's disease. The peptide should not be considered a treatment or substitute for established AD therapies. Research is at an early, exploratory stage.
How does Pinealon work at the molecular level?
Pinealon is small enough to cross cell and nuclear membranes and directly interact with DNA. Biophysical studies show it penetrates the major groove of DNA, affecting the N7 and O6 atoms of guanine (enhanced by magnesium ions). It regulates gene transcription through epigenetic mechanisms: upregulating tryptophan hydroxylase (the rate-limiting enzyme in serotonin synthesis) via interaction with the CCTGCC promoter sequence, activating PPAR-alpha and PPAR-gamma transcription factors, modulating the MAPK/ERK signaling pathway, and inducing antioxidant enzymes (SOD2, GPX1). The net effects include increased serotonin/melatonin biosynthesis, reduced oxidative stress, decreased apoptosis (via caspase-3 reduction), and promoted neurogenesis — all through direct genomic regulation rather than conventional receptor-mediated signaling.
Does Pinealon affect sleep or circadian rhythm?
Cortical-culture and docking findings suggest a possible effect on serotonin synthesis; these experiments did not demonstrate upregulation of the full pathway through melatonin. Since melatonin is the primary regulator of circadian rhythm and is synthesized in the pineal gland from serotonin, Pinealon may indirectly support circadian function and sleep quality. However, direct clinical studies measuring sleep parameters or circadian markers in Pinealon-treated patients have not been published. The connection to circadian regulation remains mechanistically plausible but clinically unverified.
Is the research on Pinealon credible?
The research is published in legitimate peer-reviewed journals indexed in PubMed (Rejuvenation Research, Molecules, Pharmaceuticals, Bulletin of Experimental Biology and Medicine, Advances in Gerontology, Journal of Physical Chemistry B). However, nearly all studies originate from Khavinson's group or closely affiliated Russian institutions. Sample sizes are small, and human studies were not randomized controlled trials. No independent replication by Western or international research groups has been published. The 2019 biophysical study in Journal of Physical Chemistry B (by Silanteva et al. at St. Petersburg State University) provides some of the most rigorous mechanistic evidence. While findings are internally consistent across models, independent validation would significantly strengthen the evidence base.